Johnson & Johnson loses battle on rheumatoid arthritis drug patent

Caitlin Wilson | | Health Exec | Economics

A federal judge told drug maker Johnson & Johnson it will not get to hold onto its patent for the rheumatoid arthritis drug Remicade.

The drug is called a biologic—it starts a reaction within the patient’s cells. Pfizer is trying to manufacture a “biosimilar” drug, called Inflectra. Johnson & Johnson filed a motion to get Pfizer’s manufacturing to halt on the basis of a patent infringement.

But the judge’s order means Pfizer will be allowed to start selling Inflectra in October, according to the New York Times.

Check out the New York Times to see the story behind the whole back and for between the two companies. 

Judge Invalidates Patent for Johnson & Johnson Rheumatoid Arthritis Drug

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Related Content

Report: 44% of adults in the U.S. are uninsured or underinsured
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation
Cardiologist demand is on the rise—can hospitals keep up?
Cardinal Health scoops up two companies for $3.9B
UnitedHealth defends $3.3B Amedisys acquisition
DOJ sues to block UnitedHealth’s $3.3B acquisition of home health giant

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”